"Developing a new drug costs from average 800 million euros and 12 years of work"
"Developing a new drug costs from average 800 million euros and 12 years of work"
Antonio Monge, professor at the University of Navarra, participated along with other experts in the II workshop of the Medicament.
"Converting a new molecule into a marketed drug costs average 800 million euros and between 10 and 12 years, with the added uncertainty that only one out of every 10,000 molecules studied will reach the market". This was stated by Professor Antonio Monge at the framework of the II conference on Medicines, organized by the School of Pharmacy of the University of Navarra and attended by more than fifty students.
Under the degree scroll "New challenges of the pharmaceutical industry", the meeting aimed to show the life cycle of a drug from its synthesis until it reaches the patient. In this sense, Antonio Monge, director of Master's Degree at research and development+I of Medicines of the academic center, warned that the future of this industry depends on the definition of a stable legal framework that allows the establishment of medium and long term commitments.
"The relationship between the sector and the Administration must be reoriented towards the conception of the sector as a factor core topic to generate wealth, not only expense; and to guarantee the sustainability of the National Health System," the expert stressed.
Influenza A vaccine
Regarding the competitiveness of the pharmaceutical industry, Antonio Monge clarified that this should be based on quality and efficacy, "not so much on costs, in which it is difficult to compete with Asian countries".
Likewise, the director of the research center in Applied Pharmacobiology (CIFA) of the University of Navarra referred to the process of creating the vaccine against Influenza A, which in spite of being done against the clock "is being carried out well. Society can be calm and confident in the decisions taken by the competent administrations".
Dr. María Ángeles Martínez-Grau, from department de Chemistry Médica de Lilly; Lidia Echevarría, from the biopharmaceutical company Noscira; Víctor Fernández, from Digna Biotech; and Dámaso Molero, director general manager of 3P Biopharmaceuticals, also took part in the II conference on Medicines.